Targeted pill to skip chemo for high-risk breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether adding a targeted pill (dalpiciclib) to standard hormone therapy can safely replace chemotherapy for women with small, hormone-positive, high-risk breast cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- Your breast cancer is small (0.5 to 2 cm), has not spread to lymph nodes, is ER-positive (≥50%) and HER2-negative.
- Your tumor has at least one high-risk feature: very fast growth (Ki-67 ≥50%), Grade 3, a high-risk gene test, or you are 40 or younger.
- You have good organ function (normal blood counts, liver, and kidney tests) and an ECOG performance score of 0 or 1.
- You have not received any cancer treatment before surgery (like chemo, radiation, or hormone therapy) and the cancer has not spread beyond the breast.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether some people with early-stage, hormone-positive breast cancer can safely skip chemotherapy and instead receive a targeted pill (ribociclib) with hormone therapy. A special blood test looks for tiny pieces of tumor DNA to help guide treatment decisions.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This study tests whether some patients with early-stage, hormone-positive breast cancer can safely skip chemotherapy and just use hormone therapy plus a CDK4/6 inhibitor pill after surgery. If you qualify, you may avoid chemo side effects while still reducing the chance of the cancer coming back.
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This study compares taking a daily pill (dalpiciclib with hormone therapy) versus standard chemotherapy before breast cancer surgery. It's for postmenopausal women with a common type of early breast cancer that is strongly hormone-receptor positive and HER2-negative.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.